Profit-taking drives MRNA pullback after surge on flu vaccine AdCom success
Profit-taking drives MRNA pullback after 39% surge on flu vaccine AdCom success
- MRNA fell ~9% on June 22, 2026, from $63.96 prior close to around $58.30 intraday despite no new negative announcement.
- Stock had surged 39% over prior 6 days and ~117% YTD after June 18 unanimous FDA panel backing of mRNA-1010 flu vaccine.
- Trefis analysis published June 22 noted 'very unattractive' valuation amid weak revenues ($0.4B in Q1 2026), ongoing losses, and high execution risks.
- Positive AdCom (9-0 vote on benefit-risk) and pending Aug 2026 FDA decision fueled recent momentum but sparked profit-taking as RSI hit overbought levels (~76).
- Fundamentals remain challenged with reliance on international COVID sales, litigation charges, and questions on flu vaccine commercial uptake versus traditional shots.
- Pullback aligns with biotech pattern of reversals after rapid hype-driven gains on pipeline news without immediate revenue impact.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.